Under the agreement, ATL will become the exclusive minority vendor for the projected sale of 40 million CoverTip(TM) syringes under federal government contracts and selected state contracts over two years. Regulatory and GMP quality control requirements are being completed by the contract manufacturer, and Medisys anticipates that the shipment, distribution and sales of its patented CoverTip(TM) syringe will occur by the end of the first quarter.

ATL provides medical supplies and products to U.S. government and state institutions, such as the Federal Bureau of Prisons, the U.S. Department of Veterans Affairs, state departments of corrections, and state mental health services agencies. ATL currently has procurement contracts with agencies in 30 states, including 13 of the 17 states that have passed safety needle legislation to protect healthcare workers against accidental needlesticks.

Ken Stone, President of ATL Industries, commented: "We believe this agreement is equally beneficial for Medisys and ATL. Significant advantages come into play when distributing through a government minority contracting company such as ours with a proven track record of contract negotiations and awards in all facets of the government procurement sector. Strong end-user financial security, guaranteed volume flow and targeted geographical product distribution create an opportunity for greater profitability. The ability to provide a superior product with federally mandated protective safety features enhances our credibility and integrity with our customers, their patients and their healthcare workers."

Medisys President and COO Kerry Frey stated: "Government healthcare facilities are an important ancillary market for CoverTip(TM) with considerable niche and sales opportunities that complement our overall focus on primary care providers and the hospital market in a regional rollout. ATL's strong background with federal and state healthcare providers matched with CoverTip(TM)'s positioning as a leading safety syringe that meets OSHA safety standards are clear-cut indications that this agreement will be long-lasting and rewarding."

About Medisys Technologies

Medisys Technologies, Inc. is a diversified medical company that develops and markets patented products for improving safety and patient care. Spurred by recent federal regulations and state safety legislation, Medisys is currently concentrating on commercializing its portfolio of patented needle safety technology. The Company has 19 patents for new safety designs, including blood collection, capillary blood testing, and tissue excision cutting needles, and has been granted 510(k) clearance by the FDA to market its CoverTip(TM) hypodermic syringe.

For more information about Medisys Technology and its proprietary suite of needle safety technologies, please contact Shayne Payne, Juan Dominguez or Dian Griesel, Ph.D. at the Investor Relations Group: 212-736-2650, or visit us on the web at www.medisystech.com.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including but not limited to economic, competitive, governmental and technological factors affecting the Company's operations, markets, products and prices and other factors discussed in the Company's various filings with the Securities and Exchange Commission.